» Articles » PMID: 17091124

Prevalence of Abnormal Serum Vitamin D, PTH, Calcium, and Phosphorus in Patients with Chronic Kidney Disease: Results of the Study to Evaluate Early Kidney Disease

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2006 Nov 9
PMID 17091124
Citations 568
Authors
Affiliations
Soon will be listed here.
Abstract

Abnormalities of mineral metabolism occur early in chronic kidney disease. Quantification of the prevalence of these abnormalities has not been described using current assays nor in large unselected populations. This outpatient cohort cross-sectional study was conducted in 153 centers, (71% primary care practices). Blood for parathyroid hormone (PTH), vitamin D metabolites, creatinine, calcium (Ca), and phosphorus (P) were drawn between June and October 2004. Low 1,25-dihydroxyvitamin D (1,25 OH2 D3) was defined as <22 pg/ml. The 1814 patients had a mean age of 71.1 years old; 48% had diabetes mellitus (DM). Low 1,25 OH2 D3 was evident at all estimated glomerular filtration rate (eGFR) levels: 13% in those with eGFR >80 ml/min, >60% in those with eGFR <30 ml/min. High PTH (>65pm/dl) occurred in 12% with eGFR >80 ml/min. Serum Ca and P were normal until eGFR was <40 ml/min. Significant differences in the mean and median values of 1,25 OH2 D3, PTH, but not 25(OH)D3 levels, were seen across deciles of eGFR (P<0.001). Multivariate analysis revealed that DM, increased urinary albumin/creatinine ratio and lower eGFR predicted lower values of 1,25 OH2 D3. A high prevalence of mineral metabolite abnormalities occurs in a large unreferred US cohort. Low 1,25 OH2 D3 and elevated PTH are common at higher eGFR than previously described. As bone, cardiovascular disease, and mineral metabolite are correlated; further studies are necessary to determine the importance of these findings relative to outcomes.

Citing Articles

Assessment of Vitamin D Metabolism Disorders in Hemodialysis Patients.

Hryciuk M, Heleniak Z, Malgorzewicz S, Kowalski K, Antosiewicz J, Koelmer A Nutrients. 2025; 17(5).

PMID: 40077644 PMC: 11901569. DOI: 10.3390/nu17050774.


Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementation.

Malberti F, Possenti S, Pecchini P, Lucca B, Marchi G, Zubani R J Nephrol. 2025; .

PMID: 40042788 DOI: 10.1007/s40620-025-02227-3.


Inhibition of MALAT1 facilitates ROS accumulation via the Keap1/HO-1 pathway to enhance photodynamic therapy in secondary hyperparathyroidism.

Wen Y, Li Y, Zhang D, Liu Z, Liu H, Li X Noncoding RNA Res. 2025; 11:249-261.

PMID: 39896343 PMC: 11787669. DOI: 10.1016/j.ncrna.2024.12.001.


Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6-year prospective study.

Liu D, Yu S, Zhang Y, Li Q, Kang P, Wang L Diabetes Obes Metab. 2025; 27(4):2232-2241.

PMID: 39895483 PMC: 11885106. DOI: 10.1111/dom.16224.


Iron Deficiency and Renal Phosphate Handling: The Role of Maximal Tubular Reabsorption of Phosphate Normalized to Glomerular Filtration Rate (TmP/GFR) in Proximal Tubular Dysfunction.

Yadav A, Narain U, Gupta A, Maurya S Cureus. 2025; 16(12):e76329.

PMID: 39850154 PMC: 11756918. DOI: 10.7759/cureus.76329.